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New Onset Diabetes After Transplantation 
(NODAT) — scientific data review
ABSTRACT 
New onset diabetes after transplantation (NODAT) is 
one of the most common and serious complications of 
solid organ transplantation. The incidence of NODAT 
is estimated to range from 2% to 53%. 
Patients who develop new onset diabetes after trans-
plantation are significantly more frequently exposed to 
a higher risk of death and cardiovascular incidents as 
well as other adverse effects, such as decreased patient 
survival, higher infection rates and early graft loss.
Identifying high-risk patients, undertaking preven-
tive action and applying appropriate treatment can 
limit the development of new onset diabetes after 
transplantation and improve a patient’s long-term 
prognosis. (Clin Diabetol 2020; 9; 5: 356–366)
Key words: new onset diabetes after transplantation, 
risk factors, diagnostics, treatment
Introduction
The second half of the 20th century was a time of 
the extremely rapid development and advancement of 
transplant medicine. Perfecting the immunosuppressive 
protocol resulted in organ transplantation becoming 
more common and consequently led to increasingly 
better postoperative care, which is conducive to ex-
tended patient survival and significantly improves 
a patient’s quality of life.
A major success was achieved in terms of early 
perioperative complications — there is a considerable 
decline in the frequency of infectious and immuno-
logical complications that influence acute rejection [1]. 
Presently, when striving to achieve further development 
with the aim of improving patient survival and qual-
ity of life, it is necessary to understand the long-term 
complications such as allograft vasculopathy or new 
onset diabetes after transplantation (and reduce them 
to the minimum) [2].
Hyperglycemia, which develops as a result of stress 
related to the transplantation surgery or the administra-
tion of high doses of steroids, persists in most patients 
exclusively during a short period of hospitalization fol-
lowing an operation. However, the administration of 
immunosuppressants, combined with predisposing risk 
factors, increases the incidence of NODAT [3].
Definition
There are several terms found in literature that de-
scribe diabetes developed after organ transplantation. 
One of them is “new onset diabetes after transplanta-
tion” (NODAT), though it exclusively encompasses those 
patients, who were diagnosed as diabetic only after 
organ transplantation and it excludes patients with 
diabetes diagnosed prior to the transplant, as well as 
those with hyperglycemia that remits over the course 
of a short period after the surgery. Cases of undiag-
nosed diabetes are related to the lack of standardized 
examination protocols before transplantation, as OGTT 
provides positive results in over 70% of patients despite 
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normal fasting plasma glucose levels being found be-
fore transplantation [4].
The term “post-transplant diabetes mellitus” 
(PTDM) has undergone changes, as initially it only 
encompassed the onset of diabetes after solid organ 
transplantation following a period of 30 days, which 
required insulin treatment. However, the term was 
reintroduced in 2014 and now encompasses patients 
with persisting hyperglycemia (most likely as a result 
of existing diabetes that failed to be diagnosed prior 
to a transplant), NODAT patients and individuals with 
temporary post-transplant hyperglycemia that remits 
within 1 year following transplantation. One of the rea-
sons for applying PTDM terminology is that screening 
tests for undiagnosed diabetes during transplantation 
are often performed ineffectively [5].
These terms do not have synonymous definitions, 
so they should not be used interchangeably, although 
they are frequently applied in such a manner.
Temporary hyperglycemia is not classified as dia-
betes, as the diagnosis can be made without ongoing 
acute rejection processes and infection, as well as after 
the immunosuppressant doses are lowered [6].
An additional term was introduced by Bloom et 
al. [7], “transplant-associated hyperglycemia” (TAH), 
which encompasses both diabetes and prediabetic 
states after organ transplantation.
Diagnosis
The diagnosis of NODAT-type diabetes is performed 
using unmodified criteria for diagnosing diabetes in 
the general population, based on acknowledged World 
Health Organization (WHO) criteria proposed by the 
American Diabetes Association (ADA) [8, 9].
The standard definition is as follows:
 — random plasma glucose concentration ≥ 200 mg/dL 
with concomitant symptoms such as polyuria, 
polydipsia and unexplained weight loss;
 — fasting plasma glucose concentration ≥ 126 mg/dL, 
where “fasting” entails at least 8 hours without 
calorie intake;
 — plasma glucose concentration ≥ 200 mg/dL two 
hours after the oral ingestion of 75 g of anhy-
drous glucose dissolved in water.
The gold standard for NODAT diagnosis is the oral 
glucose tolerance test. The fasting plasma glucose and 
HbA1c tests performed during screening examinations 
can identify high-risk patients who require further 
diagnostics [10].
Incidence
The incidence of new onset diabetes after trans-
plantation varies, depending on the transplanted 
organ, the duration of the observation period, the 
applied immunosuppressive therapy and the presence 
of risk factors. NODAT occurs in 4% to 25% of kidney 
transplant patients; 4% to 40% of heart transplant 
recipients; 30% to 35% of lung transplant patients; 
and 2.5% to 25% of liver transplant recipients [11]. The 
differences in the described incidence rates are a result 
of the lack of a uniform definition of diabetes diagnosis 
through testing as well as the lack of diagnostic meth-
ods, different patient observation periods and the pres-
ence of both modifiable and non-modifiable factors.
Therefore the discrepancy between the published 
results of various studies is considerable — the occur-
rence of NODAT is found in 2% to 53% of solid organ 
transplant recipients [12]. The incidence increases to-
gether with the time that passes after organ transplan-
tation, though the disease develops most frequently 
within the first year following surgery.
NODAT pathophysiology
The pathophysiology of the development of new 
onset diabetes after transplantation is not fully under-
stood, though it is recognized that it encompasses dys-
functions of pancreatic beta cells, increased glycogenesis 
in the liver and coexisting increased insulin resistance. 
The distinguishing aspect of new onset diabetes after 
transplantation is the original pathophysiological defect 
that is the dysfunction of pancreatic beta cells, whereas 
type 2 diabetes begins with insulin resistance [13]. Ge-
netic predispositions and individual factors also have 
significant influence on the development of NODAT.
Clinical forms
Hjelmesaeth et al. [14] proposed a division of new 
onset diabetes after transplantation into three clinical 
forms (Table 1).
NODAT risk factors
The risk factors presented in the table below 
were divided based on the possibility of modification 
(Table 2). The factors that are not subject to modifica-
tion facilitate the identification of high-risk patients, 
whereas the remaining factors serve to reduce the 




Age is the most significant risk factor for develop-
ing new onset diabetes after transplantation. In their 
study, Cosio et al. [16] demonstrated that among 2078 
kidney transplant recipients, the likelihood of develop-
ing diabetes in patients aged over 45 was 2.9 times 
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greater compared to younger patients at the time of the 
transplantation (RR = 2.2, P < 0.0001). Some authors 
place the threshold slightly higher, e.g. Ye et al. [17] 
concluded that the risk increases for an age of over 
50 years (HR = 1.20 for an age ≥ 50 years vs. < 50, 
P = 0.01). On the other hand, statistics of the United 
States Renal Data System (USRDS) indicate that an 
age of over 60 years significantly increases the risk of 
NODAT (RR = 2.6, P < 0.0001), and furthermore, the 
risk of developing diabetes increases by 1.5 times for 
every 10 years of age [18].
Ethnic group
The occurrence of new onset diabetes after 
transplantation is observed much more frequently in 
Americans of African descent and patients of Hispanic 
descent (respectively: African Americans [RR = 1.68, 
P < 0.0001] and Hispanics [RR = 1.35, P < 0.0001]) 
compared to the white population [18]. This difference 
may be related to the genetic diversity of the patients, 
and the inconsistency in pharmacokinetics and immu-
nosuppressant effects. It was also indicated that there is 
a strong diabetogenic effect in African Americans after 
the administration of tacrolimus, which influences the 
predispositions for the occurrence of NODAT.
The male sex
The publication by Dedinská et al. [19] confirmed 
the influence of the male sex as a risk factor, as well 
as the existence of significant differences with regard 
to the development of new onset diabetes after trans-
plantation. Female patients exhibit pancreatic beta 
cell dysfunctions, whereas insulin resistance and the 
metabolic syndrome are dominant in men.
Family history of diabetes
Both genetic and environmental factors influ-
ence the development of NODAT. Studies confirmed 
that the risk of developing new onset diabetes after 
transplantation increases sevenfold in first-degree 
relatives [20]. In the publication by Martinez-Castelao 
et al. [21] regarding solid organ recipients, a positive 
family history was associated with a 50% increase in 
NODAT risk.
Table 1. Division of new onset diabetes after transplantation into 3 clinical forms
I II III
Time of occurrence Very early period after  
transplantation (3–6 months)
Post-transplant period Late period  
(after 6 months)
Pathophysiology Insulin resistance due  
to high doses of GCS
Insulin synthesis  
and secretion disorders
Intensified insulin resistance
Glucose metabolism disorders Impaired insulin secretion
Treatment Diabetic diet Insulin therapy required Hypoglycemic treatment  
usually required
Lowered prednisone doses Improved glucose metabolism No plasma glucose  
improvements
Low doses administered during  
immunosuppressive therapy
Table 2. Risk factors for developing new onset diabetes after transplantation
Non-modifiable Partially modifiable Modifiable
Age > 45 years Hepatitis C Immunosuppressive therapy
Ethnic group (African American, Hispanic) CMV infection Rejection episodes
The male sex Prediabetic state Weight gain or obesity
Family history of diabetes Biochemical disorders (including  
hypermagnesemia, hyperuricemia)
Metabolic syndrome
Large number of incompatible antigens  
in the HLA system
Hypertriglyceridemia before  
transplantation
Antihypertensive medication  
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Number of incompatible antigens  
in the HLA system
The development of NODAT is associated with the 
presence of certain human leukocyte antigens (HLA): 
A30, B27 and B42 [15].
Partially modifiable risk factors
Hepatitis C
Hepatitis C infection is a predisposing factor for 
the more frequent occurrence of new onset diabetes 
after transplantation in the population of post-solid 
organ transplant patients. Studies indicate that treat-
ment using interferon alfa significantly improves 
plasma glucose levels in this group of patients. The 
pathophysiology of HCV is still unclear. It is assumed 
that the diabetogenic mechanism of the HCV infec-
tion encompasses the direct cytopathic effect of the 
virus on pancreatic beta cells, insulin resistance, and 
inhibited glycogenesis and glucose uptake in the liver 
[7]. Baid et al. [22] concluded that an HCV infection 
had an independent correlation with a 62% increase 
in insulin resistance (P = 0.0005).
CMV infection
Asymptomatic cytomegalovirus infections and 
the CMV disease are independent risk factors for new 
onset diabetes after transplantation. The studies by 
Hjelmesaeth et al. [23] found that patients with active 
cytomegalovirus infections exhibited a considerably 
lower median of insulin release compared to the control 
group, and their risk of developing NODAT was four 
times as great (RR = 4.00, P = 0.025). This depend-
ence, described during CMV infections, was most likely 
the result of the influence of inflammatory cytokines, 
which damage the pancreatic beta cells and result in 
their apoptosis [24]. The described dependence was 
confirmed in numerous publications, yet it was not 
proven in all of them [1].
Modifiable risk factors
Immunosuppressive therapy (Table 3)
 — Calcineurin inhibitors: ciclosporin and tacrolimus;
 — mTOR inhibitors: sirolimus and everolimus;
 — glucocorticosteroids.
Rejection episodes
Acute rejection is associated with a risk of de-
veloping new onset diabetes after transplantation, 
though the cause of its occurrence is idiopathic. Most 
frequently, the rejection is followed by high-dose pulse 
glucocorticosteroid (GCS) therapy, which constitutes 
the basis for the treatment of cases of acute rejection 
and which is considered to be the underlying cause of 
hyperglycemia [25].
Weight gain or obesity
Weight gain is a significant factor influencing 
the development of new onset diabetes after trans-
plantation [26], though not all publications confirm 
this dependence [27]. It is only such weight gain that 
results in overweight or obesity that is classified as 
a risk factor. Some of the patients were mal-
nourished during conservative treatment prior to 
transplantation. It was only the increase in hunger 
combined with insulin resistance and the admin-
istration of high doses of steroids at low physical 
activity that resulted in rapid weight gain. This 
emphasizes the necessity to introduce modifications 
to a patient’s lifestyle and nutritional habits before 
transplantation.
Table 3. Potential diabetogenic effects of immunosuppressants
Immunosuppressants Potential diabetogenic effects
Ciclosporin • Ø insulin secretion 
• Ø insulin synthesis
• Ø b cell density
Tacrolimus • Ø insulin secretion 
• Ø insulin synthesis
Sirolimus • ≠ peripheral insulin resistance
• impaired pancreatic b cell response
Everolimus • Ø glycolysis and pentose phosphate pathway activity
Glucocorticosteroids • Ø peripheral insulin sensitivity 
 • Inhibited pancreatic insulin production and secretion
• ≠ gluconeogenesis in the liver
• Conducive to protein degradation for amino acid release in muscles, lipolysis
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Diagnostic tools
Despite the existence of numerous studies that 
asses the risk of the occurrence of new onset diabetes 
after transplantation, there is still no detailed model of 
diagnostic methods that could be applied to post-solid 
organ transplant patients, which would enable the early 
identification of high-risk NODAT patients. As a result 
of the applied immunosuppressive therapy, plasma 
glucose levels undergo rapid changes in the early 
postoperative period. Fasting plasma glucose tests, oral 
glucose tolerance tests and HbA1c tests all evaluate a 
different scope of glucose metabolism.
The oral glucose tolerance test (OGTT) is considered 
the gold standard in NODAT diagnostics. 
Fasting plasma glucose tests (FPG) performed 
during immunosuppressive therapy do not provide an 
adequate representation of the body’s carbohydrate 
metabolism. However, FPG is preferred during outpa-
tient care since it is quick and easy to perform, as well as 
due to the low cost of testing and high patient comfort.
Glucocorticosteroids achieve their maximum ef-
fect within 8 hours after administration, which con-
sequently means that this effect is typically attained 
during afternoon hours. In the first weeks after trans-
plantation, it seems valid to perform additional plasma 
glucose tests in the afternoon [28].
Recent studies emphasize the importance of meas-
uring the level of plasma glucose during afternoon 
hours and using the level of glycated hemoglobin 
(HbA1c).
Although the results of the test provide correlations 
with the occurrence of complications of diabetes in the 
early period, considering the presence of confounding 
factors, its performance is inadvisable [29].
Clinical recommendations
Given the diagnostic difficulties, it would appear 
valid to identify patients belonging to the potential 
risk group for the development of new onset diabetes 
after transplantation, but this is problematic due to the 
numerous modifiable and non-modifiable factors that 
influence its occurrence.
However, already at the stage of NODAT diagnosis, 
the most important measure is to modify a patient’s 
lifestyle in a manner that would include changes to 
dietary habits aimed primarily at weight loss, giving 
up smoking and regular exercise.
Immunosuppressive therapy
Immunosuppressant doses need to be modified 
in order to minimize the likelihood of developing new 
onset diabetes after transplantation. In the case of 
glucocorticosteroids, it is recommended to limit the 
doses to the minimum or to terminate the administra-
tion of steroids altogether. Yet some researchers claim 
that terminating the administration of steroids during 
therapy does not provide additional benefits and it 
may furthermore intensify the risk of the occurrence of 
acute rejection. For this reason, it is important to con-
duct regular therapy monitoring in order to introduce 
hypoglycemic treatment immediately after the onset 
of the first symptoms of diabetes [14]. However, in the 
case of kidney transplant patients, steroid therapy must 
be conducted longer and with higher doses compared 
to other organ transplant recipients due to the high 
risk of rejection. In the case of tacrolimus, it is recom-
mended to lower the doses or convert to sirolimus or 
ciclosporin [30]. 
Ciclosporin (CsA)
Calcineurin inhibitors (CNI) — ciclosporin and 
tacrolimus — affect calcineurin, the T-lymphocyte-
activating protein, by inhibiting the activation of 
T-lymphocytes and the expression of cytokine genes. 
Ciclosporin damages the cells of insulin-producing 
pancreatic islets and inhibits the synthesis and glucose-
-dependent secretion of insulin. Ciclosporin extends the 
duration of action of steroids in the patient’s organism 
and influences the development of NODAT, but to an 
extent lesser compared to tacrolimus. 
Tacrolimus (Tac)
Among the immunosuppressants used in solid 
organ transplantation protocols, tacrolimus is char-
acterized by the strongest diabetogenic effects [15].
The multi-center DIRECT trial, assessing glucose 
abnormalities after kidney transplantation, described 
a significantly higher incidence of abnormal fasting 
plasma glucose levels six months after transplantation 
as well as of NODAT in patients treated using tacrolimus 
(34% vs. 26%, P = 0.046). The group of patients treated 
with tacrolimus required hypoglycemic treatment and 
significantly more frequently required therapy com-
bined with insulin [31]. 
In the studies published in 2004, Heisel et al. [32] 
discovered a higher incidence of insulin-dependent dia-
betes mellitus (IDDM) in liver, heart and lung transplant 
recipients treated with Tac. 9.8% of kidney transplant 
recipients treated with Tac developed IDDM, compared 
to 2.7% of patients treated with CsA (P < 0.00001). 
Similar tendencies were observed in recipients of solid 
organs other than kidneys — 11.1% compared to 6.2% 
respectively (P < 0.003). Not all the studies demon-
strated Tac to be more diabetogenic than ciclosporin. 
It is suggested that these discrepancies in the studies 
were partially influenced by the differences in the 
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definition of NODAT, and the differences in the doses 
of calcineurin inhibitors and the concentration of the 
medication [33].
Sirolimus
Sirolimus exhibits diabetogenic effects, whereas 
combination therapy with tacrolimus and sirolimus is 
related to a greater incidence of NODAT than in the case 
of immunosuppressive therapy using only tacrolimus 
[34]. The multi-center studies published in 2008, based 
on the analysis of the USRDS (United States Renal Data 
System) database consisting of 20,124 primary kidney 
transplant recipients receiving sirolimus, calcineurin 
inhibitors or both in various combination therapies with 
an antimetabolite — mycophenolate mofetil (MMF) or 
azathioprine (AZA) — Johnston et al. [35] demonstrated 
that patients treated with sirolimus in combination with 
CNI (CsA or Tac) exhibited the greatest incidence of 
NODAT. Furthermore, the authors found that the risk of 
developing NODAT in patients treated by means of com-
bination therapy (Sir + Tac) was 1.9 compared to pa-
tients receiving (Tac + MMF/AZA), which suggests that 
sirolimus was associated with a greater risk of NODAT 
incidence regardless of the influence of tacrolimus.
Everolimus
Everolimus is another available mTOR inhibitor. 
Although there are fewer studies assessing its mode of 
action and its influence on glucose metabolism, there 
is no data suggesting that its influence on the risk of 
developing post-transplant diabetes mellitus is different 
compared to sirolimus.
Mycophenolate mofetil (MMF)  
and azathioprine (AZA)
The antimetabolites AZA and MMF were not found 
to be diabetogenic; on the contrary — it is suggested 
that the simultaneous administration of MMF allevi-
ates the diabetogenic effects of tacrolimus. The use 
of azathioprine or MMF enables the administration 
of lower doses of other diabetogenic immunosup-
pressants. 
Summary (Table 4)
The immunosuppressive therapy must be modified 
in the event of the occurrence of post-transplant diabe-
tes mellitus. According to the KIDIGO recommendations 
it is advised to:
 — reduce the doses or terminate the administration 
of Tac, CsA and steroids;
 — replace Tac with CsA, MMF or AZA;
 — replace CsA with MMF or AZA.
Combining CNI with mTOR inhibitors (mTORi) and 
substituting mTORi for Tac is not recommended due to 
the increase in insulin resistance [36]. 
Hypoglycemic treatment
The basis for treating post-transplant patients is 
the individualization of the treatment regimen and its 
adaptation to a given patient and plasma glucose level. 
There is no common therapy model for NODAT, but rec-
ommendations for the general population are applied, 
modified on the basis of immunosuppressive therapy.
Metformin increases insulin sensitivity and is 
recommended for patients with good renal function 
(eGFR > 60 mL/min). The glomerular filtration rate often 
exhibits appropriate increase in the case of properly 
functioning grafts, thanks to which the drug can be 
safely administered to most patients and it constitutes 
the first oral medication used in the treatment of NO-
DAT. If combination therapy is required, metformin can 
be coadministered with new anti-diabetic medication 
or insulin [37].
The main disadvantage of administering metformin 
is the exposure of the patient to gastrointestinal disor-
ders as a result of the effects of immunosuppressants 
such as mycophenolate mofetil [38].
However, given the beneficial influence on body 
mass reduction, metformin is used as a first-line drug 
following body mass increase related to the administra-
tion of glucocorticosteroids.
Contraindications for the administration of met-
formin include: 
 — hypersensitivity to the active substance or to any 
excipient; 
 — diabetic ketoacidosis, diabetic pre-comatose 
state;
 — renal function failure or disorders (creatinine clea-
rance < 60 mL/min);
 — acute states with risk of renal function disorders, 
such as: dehydration, severe infection, shock, intra-
vascular administration of iodinated contrast agents;
Table 4. Summary of diabetogenic effects of immunosuppressants
Drug CsA Tac Sirolimus Everolimus MMF AZA
Glucose metabolism disorders: ++ +++ + + – –
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 — acute or chronic diseases that may result in tissue 
hypoxia, such as: heart failure or respiratory fail-
ure, recent myocardial infarction, shock;
 — liver failure, acute alcohol poisoning, alcoholism; 
 — breastfeeding.
The new generation of thiazolidinediones can be 
used without drug interaction with immunosuppressive 
therapy administered after transplantation. The use 
of thiazolidinediones in the treatment of PTDM was 
studied in cases of kidney and liver transplants, but 
not heart transplant. Several studies revealed that this 
group of drugs is effective in decreasing HbA1c both in 
monotherapy and in coadministration with other anti-
diabetic medications, with no significant interactions 
with ciclosporin and/or tacrolimus. Unfortunately, these 
studies were characterized by considerable limitations 
— first of all, there was no control group and the im-
munosuppressive treatment regimens were diverse, 
which made it difficult to provide a precise assessment 
of the treatment efficiency. Additionally, these studies 
were conducted using outdated diagnostic criteria for 
NODAT. Thiazolidinediones are strongly associated with 
a number of adverse effects — body mass increase 
(by 2% in the case of monotherapy and by 5% when 
coadministered with sulfonylureas or insulin [39], fluid 
retention and heart failure, increased risk of fractures 
in women [40] and possibly increased risk of bladder 
cancer [41]. Considering the profile of the potential 
adverse effects, particularly the likelihood of increasing 
the risk of heart failure, thiazolidinediones are cur-
rently not recommended in treatment following heart 
transplantation due to the lack of scientific evidence 
that would prove the safety of this kind of therapy in 
the aforementioned group of patients [42].
It was demonstrated that sitagliptin and vildaglip-
tin are safe and effective in treating PTDM following 
kidney or heart transplantation and no drug interac-
tion was observed with immunosuppressive prepara-
tions administered after transplantation [43]. The 
metabolism of saxagliptin is mediated by cytochrome 
CYP3A4/5, therefore its interactions with immunosup-
pressants are likely, which makes it a poor choice in 
the treatment of PTDM. Another advantage of DPP-4 
inhibitors is the possibility of their safe use in the treat-
ment of patients with renal failure — linagliptin can 
be prescribed even without reducing doses, whereas 
saxagliptin, vildagliptin and sitagliptin can also be 
administered in cases of severe renal failure if lowered 
doses are used [44]. A pleiotropic effect of DPP-4 in-
hibitors on the remodeling and cytoprotection of the 
cardiac muscle was observed in animal models [45], yet 
the SAVOR-TIMI [46] and EXAMINE trials [47] indicated 
no significant influence of saxagliptin and alogliptin 
respectively on cardiovascular outcomes. However, 
the SAVOR-TIMI study demonstrated a 27% increase 
in heart failure-related hospitalization in patients tak-
ing saxagliptin [46]. Post-hoc analyses in the EXAMINE 
[47] and TECOS [48] trials indicated no increased risk of 
heart failure following the administration of alogliptin 
and sitagliptin, suggesting that the negative influence 
of saxagliptin can be related to the drug itself and not 
the entire group. However, the FDA issued a warning re-
garding the use of sitagliptin in patients with increased 
risk of heart failure. Based on the preliminary trials of 
DPP-4 inhibitors and the recommendations of the FDA, 
sitagliptin and saxagliptin should not be administered 
to heart transplant patients. There is no clinical data 
that would make it possible to give an explicit recom-
mendation as to which type of incretin-based therapy 
would be the most beneficial in the treatment of PTDM 
after heart transplantation. The more favorable profile 
of adverse effects and the ease of administering DPP-4 
inhibitors compared to GLP-1 agonists suggests that the 
former will be better tolerated. However, the emerg-
ing reports regarding the advantages of using GLP-1 
agonists in type-2 diabetes in the context of prevent-
ing cardiovascular events demonstrate the necessity of 
conducting large-scale studies comparing these two 
types of drugs in the treatment of PTDM [42].
Despite the need for large-scale trials, current re-
ports suggest that it is appropriate to administer SGLT-2 
inhibitors to heart transplant patients. The bene ficial 
effects of these drugs in the diabetic population pri-
marily involved the significant reduction in heart failure 
incidence and heart failure-related hospitalization [49]. 
Considering these observations, research is currently be-
ing conducted on groups of non-diabetic patients with 
heart failure, therefore SGLT-2 inhibitors could potentially 
become the basis of PTDM treatment in the future.
Insulin therapy is the first-line treatment during the 
perioperative period in transplantation, but patients 
with prior diagnosed diabetes may continue the regi-
men followed before the transplantation. However, for 
patients with unbalanced plasma glucose levels, it is 
recommended to continue insulin therapy with fre-
quent plasma glucose measurements, while striving to 
lower the insulin doses with prospective modifications 
aimed at oral treatment.
Post-transplant hyperglycemia, regardless of 
whether it has been classified as NODAT or PTDM, re-
quires the introduction of intravenous insulin therapy 
and hourly monitoring of plasma glucose in the period 
directly after transplantation, particularly given the 
administration of high doses of immunosuppressants. 
Following the first week after transplantation, it should 
be replaced with subcutaneous insulin therapy, and 
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the administration of oral anti-diabetic medication 
can be considered. The subcutaneous insulin dose 
should be calculated based on its intravenous form in 
the last 24 hours. The level of plasma glucose should 
be monitored 4 times per day. Afterwards, if there are 
no contraindications, oral anti-diabetic medication can 
be introduced. 
Though the studies conducted thus far have not 
demonstrated a preferred treatment model involving 
oral anti-diabetic medication, typically the decision to 
commence therapy is based on the risk of the occur-
rence of interactions with immunosuppressants, and 
the occurrence of adverse effects (Table 5) [9, 15].
Antihypertensive therapy
The general target of arterial pressure control in 
diabetic patients is a value < 130/80 mm Hg (in indi-
viduals aged > 65 the value is < 140/80 mm Hg). The 
arterial hypertension therapy in this group of patients 
is commenced with thiazide diuretics and calcium chan-
nel blockers, which exhibit nephroprotective effects in 
patients with calcineurin inhibitors (ciclosporin, tacroli-
mus) administered in their treatment protocol. In the 
case of kidney transplant patients, while angiotensin-
converting enzyme (ACE) inhibitors and angiotensin 
receptor antagonists AT1 are preferred in the treatment 
of hypertension in patients with type 2 diabetes, the 
occurrence of renal artery stenosis must be excluded 
before they are introduced [30].
Lipid metabolism disorder treatment
The primary goal of this type of treatment is to 
decrease the concentration of LDL cholesterol. Lifestyle 
modifications and plasma glucose control are recom-
mended initially, but when the goal of treatment is 
not achieved, it is recommended to administer statins. 
Fluvastatin is recommended in the case of kidney 
transplant patients due to its nephroprotective effects. 
Furthermore, Prasad et al. [33] proved that the admin-
istration of these medications lowers the risk of devel-
oping new onset diabetes after transplantation and 
additionally decreases insulin resistance and provides 
anti-inflammatory effects. Particular attention should 
be called to the combination of calcineurin inhibitors 
with HMG-CoA reductase inhibitors, as they may result 
in rhabdomyolysis. 
It still remains to be settled whether hypertriglyceri-
demia is an independent risk factor for cardiovascular 
diseases. The therapy aimed at lowering lipid concen-
tration, statin should remain the primary strategy, but 
fibrates should be administered to patients with very 
high triglycerides, who are at risk of pancreatitis. How-
ever, no additional benefits are achieved when adding 
fibrate to statin in the case of patients with diabetes, 
which was demonstrated in the ACCORD study assess-
ing the cardiovascular risks in diabetes [50]. Further-
more, all fibrates, except gemfibrozil, are nephrotoxic, 
therefore care should be taken when administering 
these drugs to post-transplant patients, particularly in 
Table 5. Effects of oral anti-diabetic medications in post-solid organ transplant patients
Medication administered during  
the treatment of NODAT
Effects in post-transplant patients
Metformin • Safe use 
• Inadvisable during urgent hospitalization
Sulfonylureas • Higher risk of hypoglycemia
• Necessity to modify doses relative to the level of kidney failure
• Special care required in the case of elderly patients
• No influence on the pharmacokinetics of ciclosporin
Alpha-glucosidase inhibitor • No studies thus far
GLP-1 receptor agonists • Liraglutide exhibited no effect on the concentration of tacrolimus
DPP-4 inhibitors • No interactions with immunosuppressants
• Safe use
PPAR agonist • Relatively effective and safe
• Increased insulin sensitivity
• Slow initial effect
• Slight risk of hypoglycemia
• Fluid retention
SGLT-2 inhibitors • Result in dehydration and hypotension, and increased risk of genitourinary system infections
• Risk of ketoacidosis
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cases of renal failure. It was also demonstrated that 
fenofibrate decreases the concentration of ciclosporin 
in the recipient after heart transplantation. Therefore, 
administering fibrates requires great caution and the 
precise monitoring of the level of immunosuppressants, 
as well as controlling liver function and observing for 
any alarming symptoms [50].
A full lipid profile should be monitored in the case 
of all adult kidney recipients from the 2nd to the 3rd 
month following the operation, and after 2–3 months 
following a change in the immunosuppressive therapy 
or following the occurrence of other factors resulting 
in dyslipidemia. Depending on the results, KIDIGO 
prepared the following recommendations:
 — in the case of kidney recipients with fasting TG 
concentration ≥ 500 mg/dL, life style changes or 
drugs lowering triglyceride concentration should 
be introduced;
 — treatment should be introduced at LDL choles-
terol levels ≥ 100 mg/dL to lower its level below 
100 mg/dL; 
 — in the case of patients with normal LDL choleste-
rol, TG ≥ 200 mg/dL and non-HDL-ch ≥ 130 mg/dL, 
treatment should be introduced in such a way so 
as to lower the level of non-HDL-ch below 130 
mg/dL [36].
Complications
As a result of the occurrence of one of the most 
common complications of solid organ transplantation, 
new onset diabetes after transplantation, there is an 
increased risk of infection and cardiovascular incidents, 
and risk of death associated with the failure of the 
transplanted organ [46].
Summary
More and more patients have been subjected 
to solid organ transplantation in recent years. This 
provides higher chances for the improvement of their 
quality of life, but such an operation carries the risk of 
the occurrence of adverse effects such as new onset 
diabetes after transplantation. NODAT is associated 
with increased risk of acute graft rejection through 
infections, circulatory system diseases and risk of death. 
Apart from traditional risk factors concerning type 2 
diabetes, the patients are also exposed to immunosup-
pressive therapy. The early identification of high-risk 
patients during pre-transplantation screening, quick 
diagnosis and the early introduction of appropriate 
treatment as well as lifestyle modifications are all 
imperative in order to improve a patients’ long-term 
prognosis. When selecting anti-diabetic therapy for a 
post-transplant patient, the toxicity and interactions be-
tween medications have to be taken into consideration. 
Apart from hyperglycemia, the control of comorbidities 
such as dyslipidemia and arterial hypertension must 
be optimized as well. Future studies should develop 
immunosuppressive treatment regimens with minimal 
diabetogenic effects, determine the role of plasma 
glucose control in solid organ graft survival, and define 
interventions for primary prophylaxis against NODAT.
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